Cox-2 inhibitors: today and tomorrow

Area of Science:

• Pharmacology
• Inflammation Research
• Drug Development

Background:

• Inducible cyclooxygenase (COX-2) pathways mediate inflammation, prompting the development of specific COX-2 inhibitors (coxibs).
• Available coxibs include celecoxib, rofecoxib, parecoxib, valdecoxib, and etoricoxib, with ongoing development of newer agents.
• The primary therapeutic advantage of coxibs lies in their significantly reduced gastrointestinal (GI) side effects compared to traditional NSAIDs.

Purpose of the Study:

• To review the efficacy, safety, and clinical utility of coxibs.
• To compare coxibs with traditional nonsteroidal anti-inflammatory drugs (NSAIDs).
• To discuss the future role of coxibs in pain management and other potential applications.

Main Methods:

• Review of clinical trial data on coxib efficacy and safety.
• Pharmacoeconomic analysis comparing coxibs and NSAIDs.
• Discussion of emerging clinical questions and future therapeutic potential.

Main Results:

• Coxibs demonstrate efficacy comparable to traditional NSAIDs.
• Coxibs offer a significant advantage in reducing gastrointestinal complications.
• Pharmacoeconomic data suggests favorable cost-benefit ratios due to reduced GI issues and associated indirect costs.

Conclusions:

• Coxibs are likely to become first-choice anti-inflammatory drugs for acute and chronic pain and rheumatic conditions.
• Despite some remaining clinical questions (e.g., thrombosis risk), the efficacy and GI safety of coxibs support their continued clinical utility.
• Potential future applications for coxibs may include protection against malignant transformation and Alzheimer disease.